Verifying…
Home / Drug A–Z / RGI Doxycycline 100 mg Capsules

RGI Doxycycline 100 mg Capsules

NAFDAC Reg. No. A4-2490 · Drug

Registered with NAFDAC — registration activeAs of 5 November 2026 · synced automatically from official sources.
Product
RGI Doxycycline 100 mg Capsules
NAFDAC number
A4-2490
Active ingredient
Doxycycline (Doxycycline Hyclate)
Strength
100 mg
Form
Capsule
Manufacturer
Not listed
Applicant (holder)
Richygold International Limited
Approved
3 Aug 2021
Status
Inactive View on NAFDAC ↗
Registration valid to
2 Aug 2026
WHO alerts
None found
Community reports
None
Times checked
0

RxVerify commentary

  • RGI Doxycycline 100 mg Capsules is on the NAFDAC register with an active registration (A4-2490). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. Not medical advice — always follow your doctor or pharmacist.

What RGI Doxycycline 100 mg Capsules is used for

From the official U.S. FDA label for doxycycline (doxycycline hyclate), the active ingredient registered with NAFDAC.

What it is used for

To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. …

Possible side effects

Due to oral doxycycline's virtually complete absorption, side effects of the lower bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines: Gastrointestinal: anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, inflammatory lesions (with monilial overgrowth) in the anogenital region, and pancreatitis. Hepatotoxicity has been reported rarely. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Superficial discoloration of the adult permanent dentition, reversible upon drug discontinuation and professional dental cleaning has been reported. …

Do not use if

This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.

Warnings

The use of drugs of the tetracycline class during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the drugs, but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. Use doxycycline in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g., anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies. …

Pregnancy & breastfeeding

Pregnancy: Teratogenic Effects There are no adequate and well-controlled studies on the use of doxycycline in pregnant women. The vast majority of reported experience with doxycycline during human pregnancy is short-term, first trimester exposure. There are no human data available to assess the effects of long-term therapy of doxycycline in pregnant women, such as that proposed for treatment of anthrax exposure. …

General information only — not dosing advice. Always follow the leaflet in your pack and your doctor or pharmacist.

Check your pack of RGI Doxycycline 100 mg Capsules

Add the expiry date printed on your pack for a full Trust Score — or look up uses, side effects and cheaper generics.

3 free checks left today · no signup Official sources: NAFDAC Green Book & recalls · WHO · U.S. FDA · NLM RxNorm

About RGI Doxycycline 100 mg Capsules

What is in RGI Doxycycline 100 mg Capsules?

RGI Doxycycline 100 mg Capsules contains Doxycycline (Doxycycline Hyclate) (100 mg), as capsule, according to its NAFDAC registration record.

Is RGI Doxycycline 100 mg Capsules registered with NAFDAC?

Yes. RGI Doxycycline 100 mg Capsules is listed on the NAFDAC register under registration number A4-2490, and its registration is active as of 5 November 2026.

Has RGI Doxycycline 100 mg Capsules been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches RGI Doxycycline 100 mg Capsules in our automatically synced alert list.

How can I check that my pack of RGI Doxycycline 100 mg Capsules is genuine?

Run a free authenticity scan with the NAFDAC number A4-2490, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

What is RGI Doxycycline 100 mg Capsules used for?

To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. I (Summarised from the official U.S. FDA label for doxycycline (doxycycline hyclate). Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used RGI Doxycycline 100 mg Capsules? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from RxVerify users, not medical advice. Report side effects to your doctor and to NAFDAC.